Screener
First Tracks Biotherapeutics Inc TRAX Financing Cash Flow
Financing Cash Flow at other companies
Where this comes from
Reported directly by First Tracks Biotherapeutics Inc in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224190
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by investing activities | 34,983 | 14,847 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Net parent investment | 7,851 | 5,716 |
| Net cash provided by financing activities | 7,851 | 5,716 |
| Net increase (decrease) in cash and cash equivalents | 10,273 | (24,443) |
| Cash and cash equivalents, beginning of period | 238,196 | 123,080 |
| Cash and cash equivalents, end of period | $248,469 | $98,637 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |
Item 1. Combined Financial Statements.
FAQ
- What is First Tracks Biotherapeutics Inc's financing cash flow?
- First Tracks Biotherapeutics Inc (TRAX) reported financing cash flow of $7.85M in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about First Tracks Biotherapeutics Inc's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude